BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
WEZLANA (ustekinumab-auub) by Amgen is interleukin-12 antagonists [moa]. Approved for interleukin-12 antagonist [epc]. First approved in 2023.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEZLANA (ustekinumab-auub) is an Amgen-sponsored monoclonal antibody biosimilar referencing Johnson & Johnson's STELARA, targeting interleukin-12 to treat immune-mediated inflammatory diseases. It blocks IL-12 signaling to reduce pathogenic immune responses in conditions like psoriasis, psoriatic arthritis, and Crohn's disease. Administered via intravenous or subcutaneous injection, it offers clinicians a biosimilar alternative in an established therapeutic class.
Growth
Early-stage biosimilar in growth phase with moderate competitive pressure (30); commercial team likely expanding to capture market share from established reference product.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WEZLANA offers career opportunities in biosimilar commercialization, where success hinges on payer negotiations, access strategy, and competitive differentiation rather than clinical innovation. Roles emphasize market access, managed care, and field execution to capture share from the reference product in a mature market.
Brand Manager
Worked on WEZLANA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.